Our Pipeline

What if veterinarians could apply advances in human health to provide better therapeutic options for dogs and cats? At Aratana Therapeutics, we’re asking more than “what if” — we’re asking how and when. As a new kind of animal health company, our sole focus is on how to solve unmet and underserved medical needs in pets with serious diseases. We are working to bring together the intersection of advances in human biotechnology and veterinary medicine to develop solutions with the goal to help raise the standard of care for medical conditions in pets.

As we hope our portfolio indicates, we’re passionate about giving veterinarians, pet owners and their pets therapeutic options based on cutting-edge science, as well as proven safety and effectiveness studies in pets. We are committed to evidence-based medicine. We run pilot and pivotal studies and analyze data to evaluate both the safety and efficacy of novel therapeutics that have the potential to give pets with serious conditions a new beginning. Ultimately, these studies are crucial in helping to improve medical treatments and outcomes for pets.

Aratana has specialized experience to move new pet therapeutics through the process of formulation development, pre-clinical and clinical evaluation, regulatory approval, manufacturing and commercialization. In addition to our approved or licensed therapeutics, we have several novel therapeutics in development for pain, viral diseases, allergy and cancer that have the potential to improve the quality of lives for dogs and cats.

Take a look at our exciting portfolio that includes our FDA-approved therapeutics and investigational therapeutic candidates.

Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) Regulated Therapeutics

  • ENTYCE® (capromorelin oral solution) for appetite stimulation in dogs
  • GALLIPRANT® (grapiprant tablets) for the control of pain and inflammation associated with osteoarthritis in dogs
  • NOCITA® (bupivacaine liposome injectable suspension) for local post-operative analgesia for cranial cruciate ligament surgery in dogs
  • NOCITA® (bupivacaine liposome injectable suspension) as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats
  • AT-002 management of weight loss in CKD cats
  • AT-006 feline herpes virus
  • AT-018 atopic dermatitis in dogs

United States Department of Agriculture (USDA) Center for Veterinary Biologics (CVB) Regulated Therapeutics

  • Canine Osteosarcoma Vaccine, Live Listeria Vector (AT-014) for dogs

This information reflects public disclosure current as of August 3, 2018.

IMPORTANT SAFETY INFORMATION

ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency.  Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.

GALLIPRANT® (grapiprant tablets) is not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.

NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCI, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.

NOCITA® (bupivacaine liposome injectable suspension) is for use as a peripheral nerve block in cats only. Do not use in cats younger than 5 months of age, that are pregnant, lactating, or intended for breeding. Do not administer by intravenous or intra‐arterial injection. Adverse reactions in cats may include elevated body temperature, infection or chewing/licking at the surgical site. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.